Clinical trials: Allergic Rhinoconjunctivitis
Allergic Rhinitis, Allergic Rhinoconjunctivitis
SUBLIVAC FIX Phleum Pratense DT/DRF
The aim of the study is to determine the optimal effective dose of SUBLIVAC FIX Phleum pratense based on reduction of upper airways reactivity after 5 months of treatment with different dosages of SUBLIVAC FIX Phleum pratense…
- Trial name
- NCT01682070
- Testing
- SUBLIVAC FIX phleum prat.
- Where
- 23 sites in Germany, Poland
- Volunteers
- 266 people
- Sponsor
- HAL Allergy
Allergy
Safety of ToleroMune Ragweed to Treat Ragweed Allergy in Ragweed Allergic Subjects With Rhinoconjunctivitis
It is estimated that 36 million Americans suffer from seasonal allergies and that ragweed is the primary cause of autumn allergies, 87% of patients with ragweed allergy suffer rhinoconjunctivitis.
- Trial name
- NCT00878774
- Testing
- ToleroMune Ragweed
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Circassia Limited
Seasonal Allergic Rhinoconjunctivitis
Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis
The purpose of this study is to determine whether the oral administration of grass pollen peptides is safe and effective in the treatment of allergic rhinitis.
- Trial name
- NCT00833066
- Testing
- gpASIT+TM
- Where
- 4 sites in Belgium
- Volunteers
- 54 people
- Sponsor
- BioTech Tools S.A.
Perennial Allergic Rhinitis
Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension
Double-blind phase: The objective of the study was to evaluate the efficacy and safety of Bilastine 20 mg, compared to Cetirizine and placebo for the treatment of perennial allergic rhinitis.
- Trial name
- NCT01127620
- Testing
- Bilastine, Cetirizine
- Volunteers
- 650 people
- Sponsor
- Faes Farma, S.A.
Allergic Rhinoconjunctivitis
Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children
Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens formulated as solution in comparison to a symptomatic standard treatment with add on placebo in grass pollen allergic children suffering…
- Trial name
- NCT00841256
- Testing
- Grass pollen allergens in a water/glycerol solution
- Where
- Germany
- Volunteers
- 207 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Rhinoconjunctivitis
Tolerability of Grazax in Patients With Hayfever in Real Life Settings
The purpose of this study is to assess the safety profile of specific immunotherapy with Grazax for three consecutive grass pollen seasons.
- Trial name
- GRAAL (NCT01433510)
- Testing
- Grazax
- Where
- France
- Volunteers
- 628 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinoconjunctivitis, Birch Pollen Allergy
Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma
Allergic rhinoconjunctivitis due to birch pollen is a seasonal problem which manifests as a combination of nasal symptoms (such as congestion, runny nose, sneezing, itching of the nose) and ocular symptoms (such as red, itchy and…
- Trial name
- YOBI (NCT05668390)
- Testing
- STALORAL® Birch 300 IR
- Where
- 62 sites in Austria, Bulgaria and 10 more
- Volunteers
- 553 people
- Sponsor
- Stallergenes Greer
Allergic Rhinitis
A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of…
- Trial name
- NCT02557633
- Testing
- Grass MATA MPL 10200, Grass MATA MPL 18200
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Allergy Therapeutics
Allergic Rhinitis and/or Rhinoconjunctivitis +- Asthma, Immunotherapy, Allergen
Dose Finding Study for Depigoid Birch: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma
Specific immunotherapy for subcutaneous application: Dose finding study to evaluate the correct dose. 4 concentrations of a birch pollen allergen extract are applied in this study. Duration of therapy 20 weeks.
- Trial name
- NCT01144429
- Testing
- Allergoid, allergenic extract of 100% Birch
- Where
- 39 sites in Germany, Lithuania and 1 more
- Volunteers
- 344 people
- Sponsor
- Leti Pharma GmbH
Grass Allergy, Rhinoconjunctivitis
ToleroMune Grass Exposure Unit Study
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal…
- Trial name
- NCT01385800
- Testing
- ToleroMune Grass
- Where
- Canada
- Volunteers
- 280 people
- Sponsor
- Circassia Limited
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
The purpose of this study is to assess safety, tolerability and demonstrate a dose response signal using Total Symptom Score (TSS), based on challenges with grass pollen in an Environmental Exposure Chamber (EEC), followed by…
- Trial name
- NCT02556801
- Testing
- SUBLIVAC FIX Phleum Prat.
- Where
- Canada
- Volunteers
- 168 people
- Sponsor
- HAL Allergy
Cat Allergy, Cat Hypersensitivity
A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy
The goal of this study is to identify changes in cells that are related to the treatment with Cat-PAD (ToleroMune Cat).
- Trial name
- NCT02311413
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Allergic Rhinoconjunctivitis
Efficacy and Safety of Grass Pollen Sublingual Immunotherapy
The study is assessing efficacy and safety of three different dosage regimens of grass pollen sublingual immunotherapy in adult patients suffering from grass pollen related rhinoconjunctivitis.
- Trial name
- NCT00567346
- Testing
- Oralgen, grass pollen extract
- Where
- 40 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 605 people
- Sponsor
- Artu Biologicals
Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate…
- Conditions
- Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis, House Dust Mite Allergy, Pollen Allergy
- Trial name
- NCT04874714
- Testing
- MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000)
- Where
- 13 sites in Spain
- Volunteers
- 18 people
- Sponsor
- Inmunotek S.L.
Cat Allergy, Rhinoconjunctivitis
Cat-PAD Follow on Study
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT01272323
- Testing
- Cat-PAD Dose 1, Cat-PAD Dose 2
- Where
- Canada
- Volunteers
- 170 people
- Sponsor
- Circassia Limited
Allergic Rhinoconjunctivitis, Allergic Asthma
Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
The CSMS was defined by the European Academy of Allergy and Immunology Taskforce as a standardised tool to assess clinical effects of allergen-specific immunotherapy (AIT).
- Trial name
- NCT03850626
- Testing
- Immunotherapy
- Where
- Germany
- Volunteers
- 168 people
- Sponsor
- Leti Pharma GmbH
Rhinitis, Allergic, Conjunctivitis
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641/Amb a 1-U) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period.
- Trial name
- NCT00770315
- Testing
- Ambrosia artemisiifolia allergen extract (Amb a 1-U)
- Volunteers
- 784 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinoconjunctivitis
A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube
The objective of this study is to evaluate ocular and nasal signs and symptoms in patients with seasonal allergic rhinoconjunctivitis following allergen exposure in the Allergen BioCube.
- Trial name
- NCT00985075
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- ORA, Inc.
Allergic Rhinoconjunctivitis
A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)
This study will gather information on allergic rhinoconjunctivitis from surveys completed by adults and children.
- Trial name
- AIRS (NCT01535118)
- Volunteers
- 2,765 people, healthy volunteers welcome
- Sponsor
- ALK-Abelló A/S
Rhinoconjunctivitis, Allergic Asthma
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
To evaluate efficacy and tolerability of specific subcutaneous immunotherapy with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense) in subjects with rhinoconjunctivitis caused by grass pollen…
- Trial name
- NCT01353755
- Testing
- Grass pollen specific immunotherapy, Placabo
- Where
- Germany
- Volunteers
- 195 people
- Sponsor
- Allergopharma GmbH & Co. KG